DBV TECHNOLOGIES News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.06.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 (GlobeNewswire)
04.06.20	DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 (GlobeNewswire)
02.06.20	DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference (GlobeNewswire)
12.05.20	Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 (GlobeNewswire)
30.04.20	DBV Technologies Reports March 31, 2020 Cash Position (GlobeNewswire)
20.04.20	DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting (GlobeNewswire)
15.04.20	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
10.04.20	Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic (GlobeNewswire)
30.03.20	Ordinary and Extraordinary General Meeting of April 20, 2020 (GlobeNewswire)
26.03.20	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
20.03.20	DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F (GlobeNewswire)
17.03.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 (GlobeNewswire)
16.03.20	DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years (GlobeNewswire)
04.03.20	DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update (GlobeNewswire)
04.03.20	DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering (GlobeNewswire)
02.03.20	DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (A (GlobeNewswire)
24.02.20	DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 (GlobeNewswire)
21.02.20	DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children (GlobeNewswire)
10.02.20	DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference (GlobeNewswire)
07.02.20	Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 (GlobeNewswire)
06.02.20	DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer (GlobeNewswire)
04.02.20	DBV Technologies Announces Closing of Global Offering (GlobeNewswire)
30.01.20	DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (GlobeNewswire)
29.01.20	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position (GlobeNewswire)
15.01.20	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
14.01.20	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
08.01.20	DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy (GlobeNewswire)
02.01.20	DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer (GlobeNewswire)
10.12.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
19.11.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
05.11.19	DBV Technologies to Present at the Stifel 2019 Healthcare Conference (GlobeNewswire)
24.10.19	DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 (GlobeNewswire)
16.10.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
15.10.19	DBV Technologies Announces Closing of Global Offering (GlobeNewswire)
10.10.19	DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs (GlobeNewswire)
09.10.19	DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (GlobeNewswire)
08.10.19	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position (GlobeNewswire)
04.10.19	DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy (GlobeNewswire)
02.10.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
19.09.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
07.08.19	DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy (GlobeNewswire)
01.08.19	DBV Technologies Reports First Half 2019 Financial Results (GlobeNewswire)
18.07.19	Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report (GlobeNewswire)
12.07.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
26.06.19	DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer (GlobeNewswire)
11.06.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
03.06.19	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
01.06.19	DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 (GlobeNewswire)
24.05.19	DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors (GlobeNewswire)
14.05.19	DBV Technologies Announces Departure of Deputy CEO David Schilansky (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DBV TECHNOLOGIES

Aktien Top/Flop

Meistgelesene Nachrichten